MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/
MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC)
The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education.
Optimized 3D Solution for Medical Training and Research
The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK.
It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software installed on a PC.
This configuration enables 3D visualization while utilizing the customer’s existing imaging infrastructure, requiring no additional hardware replacement.
Proven Performance in Clinical Environments
Many leading hospitals in Korea have already adopted MOPIC’s display for surgical video review and educational simulation.
Medical professionals reported that the system delivers the same sense of depth and dimensionality as a real surgical scene, improving surgical understanding and enhancing collaboration among medical teams.
Key Advantages
- Precise Depth Perception: Clearly identifies complex surgical, microbial, and molecular structures
- Enhanced Training and Collaboration: Enables real-time sharing and review of 3D surgical videos
- Easy Integration: Achieves 3D visualization using existing 2D infrastructure
The new 32-inch display is a dedicated B2B solution designed for hospitals, medical device manufacturers, and monitor producers. It can be delivered as a customized ODM model or as a white-label product, providing flexibility to meet various customer needs. The display offers a practical path to achieving higher realism and precision in medical imaging.
MOPIC will showcase the 32-inch autostereoscopic 3D display at CES 2026 (Booth: Central #15457), where visitors can experience live demonstrations of autostereoscopic 3D medical imaging.
Meeting requests for CES can be arranged through the official MOPIC website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251029144650/en/
Contacts
MOPIC Co., Ltd.
Jeesoo Jung
info@mopic.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow29.10.2025 11:12:00 EET | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced today its Q3 2025 results, summarizing financial performance year-to-date ending 30 September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029815979/en/ Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow Year-to-Date Financial Highlights as of Q3 2025: Positive free cash flow EUR 3.2 (–2.2) million, sixth consecutive quarter of cash-positive operations. Revenue in constant currency EUR 56.6 (54.0) million, +4.8%. EBIT in constant currency EUR 14.9 (13.0) million, +15.0%. Annual recurring revenue EUR 25.1 (23.2) million, +8%. Order backlog EUR 105.5 (75.1) million, +40%. Commenting on the results for the third quarter of 2025, Padma Ravichander, CEO of Tecnotree, says: “Tecnotree’s Q3 2025 results reflect our disciplined focus on profitable order book execution, with year-to
Domaine Worldwide and Shopify Launch Enterprise Platform Migration Initiative Across Europe29.10.2025 11:00:00 EET | Press release
Domaine Worldwide, the leading global Shopify design and development partner, announced the launch of its European Platform Migrations partnership with Shopify today. The initiative positions Domaine as the go-to commerce partner for enterprise-level brands across the UK, DACH, and BENELUX regions looking to migrate to Shopify’s scalable, commerce-ready infrastructure. As enterprise organizations across Europe face the challenge of modernizing legacy systems, this campaign highlights the combined power of Domaine’s migration expertise and Shopify’s enterprise-grade flexibility—offering brands a seamless path to improved performance, agility, and long-term growth. “For enterprise retailers, platform migration is no longer just a technical decision—it’s a strategic one. For some, it's become a strategic imperative,” said Marko Bon, Co-founder and President of Domaine. “We’ve seen first-hand how a migration to Shopify is a foundational step in digital business transformation, unlocking st
NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 09:44:00 EET | Press release
NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c
Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 09:00:00 EET | Press release
Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performance, and reliable supply are crucial to integrating recycled materials. “We are proud to enter into this partnership with H&M Group. Reliable acces
Samsung Bioepis to Commercialize BYOOVIZ ® (ranibizumab) in Europe from January 202629.10.2025 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, at Samsung Bioepis. “Samsung Bioepis will continue to broaden our reach to patients across Europe by reinforcing our leadership and expertise in biosimilars.” B
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom